Frontlight ResearchEarly access
Gaucher disease trials in United States
14 of 17 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleNatural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
- Where
- Bethesda
- Age
- 1 day to 100 years
- People
- 200
- Run by
- National Human Genome Research Institute (NHGRI)
See details and how to joinNCT00029965 - No phaseTaking peopleParkinson's Disease in Type 1 Gaucher Disease
- Where
- New York
- Age
- 40 years and over
- People
- 100
- Run by
- Icahn School of Medicine at Mount Sinai
See details and how to joinNCT07886879 - No phaseTaking peopleOxidative Stress and Inflammatory Biomarkers in Gaucher Disease
- Where
- Minneapolis
- Age
- 18 years to 75 years
- People
- 34
- Run by
- University of Minnesota
See details and how to joinNCT02437396 - No phaseEnrolling by invitationGenetic Studies of Lysosomal Storage Disorders
- Where
- Bethesda
- Age
- 1 week to 110 years
- People
- 1,000
- Run by
- National Human Genome Research Institute (NHGRI)
See details and how to joinNCT00001215 - No phaseTaking peopleInternational Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
- Where
- Ann Arbor, Aurora, Baltimore, Beverly Hills, Boston, Camden, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Coral Gables, Coral Springs, Dallas, Decatur, Detroit, Dublin, Durham, Fairfax, Fort Worth, Grand Rapids, Greenville, Hackensack, Hershey, Huntington, Indianapolis, Iowa City, Jacksonville, Kansas City, Las Vegas, Little Rock, Los Angeles, Louisville, Milwaukee, Minneapolis, Morristown, Nashville, New Brunswick, New Haven, New Hyde Park, New Orleans, New York, Norfolk, Omaha, Orange, Paterson, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Rochester, Sacramento, Salt Lake City, San Diego, San Francisco, Seattle, Stanford, St Louis, Syracuse, Tacoma, Tampa, Tucson, Valhalla, Washington D.C.
- People
- 12,000 worldwide
- Run by
- Genzyme, a Sanofi Company
See details and how to joinNCT00358943 - No phaseTaking peopleGaucher Disease Outcome Survey (GOS)
- Where
- Lexington
- People
- 1,257
- Run by
- Shire
See details and how to joinNCT03291223 - No phaseTaking peopleA Long-term Follow-up Study of Gaucher Disease
- Where
- Durham
- People
- 200
- Run by
- Duke University
See details and how to joinNCT03190837 - No phaseTaking peopleAdvancing Integrated Therapies for Gaucher Disease
- Where
- New Haven
- Age
- 3 months to 75 years
- People
- 30
- Run by
- Yale University
See details and how to joinNCT07758816 - No phaseTaking peopleMAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
- Where
- Minneapolis
- Age
- 18 years to 80 years
- People
- 5
- Run by
- University of Minnesota
See details and how to joinNCT05586243 - No phaseEnrolling by invitationScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
- Where
- Brooklyn, Manhasset, New York, Queens, The Bronx
- Age
- Up to 4 weeks
- People
- 100,000
- Run by
- Albert Einstein College of Medicine
See details and how to joinNCT05368038 - No phaseTaking peopleRegistry of Patients Diagnosed With Lysosomal Storage Diseases
- Where
- San Francisco
- Age
- Up to 64 years
- People
- 250
- Run by
- University of California, San Francisco
See details and how to joinNCT05619900 - No phaseTaking peopleExtracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
- Where
- Minneapolis
- Age
- 18 years to 80 years
- People
- 30
- Run by
- University of Minnesota
See details and how to joinNCT05843552 - No phaseTaking peopleLongitudinal Study of Neurodegenerative Disorders
- Where
- Pittsburgh
- People
- 1,500
- Run by
- University of Pittsburgh
See details and how to joinNCT03333200 - No phaseTaking peopleData Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
- Where
- Pittsburgh
- Age
- 2 months to 60 years
- People
- 50
- Run by
- Paul Szabolcs
See details and how to joinNCT04528355